The original research company of Dacomitinib (Vizimpro) is Pfizer Inc. of the United States. It is a highly effective second-generation EGFR tyrosine kinase inhibitor, mainly used for the treatment of metastatic non-small cell lung cancer (NSCLC) with positive epidermal growth factor receptor (EGFR) mutations. What are the purchase channels for Dacomitinib?
Purchase Channels for Dacomitinib
There are various purchase channels for Dacomitinib, but choosing formal channels is a prerequisite for ensuring drug quality and medication safety.
Purchase from Formal Hospitals and Pharmacies
In China, Dacomitinib has been launched and included in the national medical insurance. Patients can purchase it through formal hospitals and pharmacies. The advantage of this channel is that the drug source is regular, and patients can enjoy the preferential policies of medical insurance. When purchasing, patients need to bring the prescription issued by a doctor and follow the drug purchase procedures of the hospital or pharmacy.
Overseas Drug Purchase
For some patients, overseas drug purchase may be an option. The original Dacomitinib exported by Pfizer to India, as well as generic versions from countries such as Bangladesh and Laos, are available in the market. Overseas drug purchase involves many risks. Patients who choose to purchase drugs overseas should carefully screen the source of the drugs, understand the relevant laws and regulations, and avoid using illegal channels.
Medication for Special Populations of Dacomitinib
Special caution is required when using Dacomitinib in special populations.
Pregnant and Lactating Women
Pregnant and lactating women need to conduct a comprehensive risk assessment before using Dacomitinib. Animal studies have shown that Dacomitinib may cause harm to the fetus. Pregnant women should avoid using Dacomitinib, and women of childbearing age should take effective contraceptive measures during treatment. Lactating women should avoid breastfeeding during treatment and for at least 17 days after stopping the drug.
Patients with Hepatic or Renal Impairment
For patients with hepatic or renal impairment, dosage adjustment should be considered when using Dacomitinib. Patients with mild or moderate hepatic or renal impairment usually do not need dosage adjustment, but the recommended dosage for patients with severe impairment has not been established. Such patients should consult a professional doctor before taking the drug and formulate a personalized medication plan according to their specific conditions.
Drug Interactions of Dacomitinib
Interactions between Dacomitinib and other drugs may affect its efficacy and safety.
Interaction with Proton Pump Inhibitors (PPIs)
Proton pump inhibitors can significantly reduce the blood concentration of Dacomitinib, thereby reducing its efficacy. Concurrent use of Dacomitinib with PPIs should be avoided. If antacid drugs are indeed needed, it is recommended to choose locally acting preparations or H2 receptor antagonists, and adjust the medication time.
Effect on CYP2D6 Substrates
Dacomitinib can increase the blood concentration of CYP2D6 substrates, which may lead to toxic reactions. For CYP2D6 substrates that can cause severe or life-threatening toxicity even with a slight increase in concentration, concurrent use with Dacomitinib should be avoided.
During the use of Dacomitinib, patients should also avoid concurrent use of other drugs that may cause interactions. Before using combined medications, patients should consult a professional doctor or pharmacist to understand the information about drug interactions.
